[1] Bosch FX,Ribes J,Cleries R,et al. Epidemiology of hepatocellular carcinoma. Clinical Liver Disease,2005,9:191-211. [2] 吴孟超.肝脏外科的回顾、现状及展望.中国实用外科杂志,2000,20(1):5-6. [3] Murata S,Mine T,Ued T,et al. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. Sci World J,2013,Mar 27,479805. [4] Doyon D,Mouzon A,Jourdeetal AM,et al. Hepatic arterial embolization in patients with malignant liver tumors. Annales de Radiologie,1974,36:593-603. [5] Llovet JM,Real MI,Montana X,et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial.Lancet,2002,359:1734-1739. [6] Lo CM,Ngan H,Tso WK. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology,2002,35(5):1164-1117. [7] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival. Hepatology,2003,36:429-442. [8] Luo J,Peng ZW,Guo RP,et al. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large,multiple,and resectable hepatocellular carcinomas:A prospective nonrandomized analysis. Radiology,2011,259(1):286-295. [9] Shi M,Chen JA,Lin XJ,et al. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol,2010,16(2):264-269. [10] 王建华,周康荣. 肝癌综合性介入治疗规范化方案(草案). 临床放射学杂志,2002,21(7):497-500. |